文献速递皮肤肿瘤

英格兰2016-2021年黑色素瘤BRAF检测与生存全国队列研究

A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England from 2016 to 2021.
PubMed 文献 · Br J Dermatol · 2025-01-01

该研究基于英格兰国家疾病登记服务数据,纳入2016至2021年新诊断黑色素瘤患者,分析BRAF分子检测频率、患者/肿瘤特征与BRAF突变的关联及生存。结果显示仅14%患者登记了BRAF检测,成功检测肿瘤中34%存在BRAF突变,BRAF突变患者5年净生存率较低,尤其在II期疾病。

要点

  • 英格兰黑色素瘤BRAF检测率低且存在地理和人口学差异。
  • 成功检测的肿瘤中约三分之一存在BRAF突变,女性及年轻患者更常见。
  • BRAF突变与较低的5年净生存率相关,尤其在II期患者中。

核心结论

  • 英格兰黑色素瘤BRAF检测存在地理和人口学差异,BRAF突变影响生存率,尤其在II期疾病中。

研究设计与样本

  • 全国回顾性队列研究,使用英格兰国家疾病登记服务 population-based 数据,纳入2016至2021年所有新诊断黑色素瘤及分子BRAF检测。

主要发现

  • 新发黑色素瘤中14%(n=13 138/91 415)登记了BRAF检测。
  • 成功检测的肿瘤中BRAF突变比例为34%(n=4424/13 012)。
  • 西米德兰兹郡检测比例最高(23%,n=1783/7901),约克郡和亨伯最低(11%,n=856/7760)。
  • 女性(OR 0.82,95%CI 0.79-0.86)和年龄>80岁(OR 0.88,95%CI 0.83-0.93)患者检测可能性较低。
  • BRAF突变与女性性别相关(OR 1.16,95%CI 1.07-1.26),年龄>80岁患者BRAF突变 odds 较低(OR 0.36,95%CI 0.32-0.40)。

临床怎么用

  • 应确保一致、早期和准确的BRAF检测,以指导治疗决策并促进公平护理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inadequacy of testing for melanoma BRAF status results in delayed access to systemic therapy. BRAF mutations and their association with patient/tumour characteristics and survival is poorly understood. OBJECTIVES: To report national data from England on the frequency of molecular BRAF testing; the association of patient/tumour characteristics with BRAF mutations; and the treatment and survival of patients with BRAF mutations. METHODS: This national retrospective cohort study identified all new melanomas and molecular BRAF testing in England diagnosed from 2016 to 2021 using population-based data from the National Disease Registration Service. Multivariate logistic regression determined the association between BRAF testing with patient/tumour characteristics and BRAF genotype with patient/tumour characteristics. Age-standardized net survival analysed melanoma-specific mortality by BRAF genotype. RESULTS: Of new cases of melanoma, 14% (n = 13 138/91 415) had a BRAF test registered. The proportion of successfully tested tumours that were BRAF-mutated was 34% (n = 4424/13 012). The West Midlands tested the highest proportion of cutaneous tumours (23%; n = 1783/7901) vs. the lowest in Yorkshire and the Humber (11%; n = 856/7760). Female patients [odds ratio (OR) 0.82, 95% confidence interval (CI) 0.79-0.86] and those aged > 80 years (OR 0.88, 95% CI 0.83-0.93) were less likely to be tested for BRAF mutations. BRAF mutations were associated with female gender (OR 1.16, 95% CI 1.07-1.26). Patients aged > 80 (OR 0.36, 95% CI 0.32-0.40) had lower odds of having BRAF-mutated tumours. Patients with BRAF mutations had a lower 5-year net survival [55.9% (95% CI 52.7-59.2) vs. BRAF wildtype 5-year net survival 66.5% (95% CI 62.1-60.1)], particularly in stage II disease. CONCLUSIONS: This study presents the largest dataset on national melanoma BRAF status published to date. The data highlight geographical and demographic variations in BRAF testing and the impact of BRAF mutations on survival rates, particularly in patients with stage II disease. This highlights the critical role of consistent, early and accurate testing to ensure equal care, guide treatment decisions and understand prognosis. Melanoma is a type of skin cancer. It is relatively common and can affect a patient’s quality of life. Sometimes it results in death. Our body contains DNA which contains instruction for how the body can grow and work. Tiny parts of DNA are called genes. One of these genes is called ‘BRAF’. When the BRAF gene is changed, it is ‘mutated’. Certain BRAF mutations can result in melanoma. We can test a sample of a patient’s melanoma to find out if there is a BRAF mutation. There are treatments available that work on targeting BRAF mutations. The BRAF gene is the most common and important mutation in melanoma. However, it is largely unknown how common BRAF mutations are, what the risk factors are for getting them and how they may affect survival. This is the largest study ever reported on BRAF mutations in melanoma. We used data from the English National Cancer Registry to look at over 13,000 melanomas from patients living in England. We found that around 1 in 3 patients with melanoma had a BRAF mutation. There were differences in the likelihood of being tested for a BRAF mutation based on where in England the patients lived and other factors such as age or gender. Female patients, younger patients and patients with melanoma on their chest or back were more likely to have a BRAF mutation. Also, patients with a BRAF mutation were more likely to die from melanoma by 5 years after their diagnosis. Our study highlights the differences in BRAF testing and the impact of BRAF mutations on survival. Appropriate, early and accurate BRAF testing are important to ensure equal care, guide treatment decisions and better understand patient outcomes.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Mistry K, Jeffrey P, Levell NJ, et al. A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England from 2016 to 2021. Br J Dermatol. 2025. PMID: 40902091. doi:10.1093/bjd/ljaf351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。